1. Atzpodien J, Korfer A, Evers P, Franks CR, Knuver-Hopf J, Lopez-Hanninen E, Fischer M, Mohr H, Dallmann I, Hadam M, Hubert P, Kirchner H (1990) Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study. Mol Biother 2: 18
2. Ballas ZK, Rasmussen W (1987) Lymphokine-activated killer (LAK) cells. III. Characterization of LAK precursors and susceptible target cells within the murine thymus. J Immunol 139: 3542
3. Bloomgren H, Anderson B (1969) Evidence for a small pool of immunocompetent cells in the mouse thymus. Exp Cell Res 57: 185
4. Brunda MJ, Bellantoni D, Sulich V (1987) In-vivo anti-tumor activity of combinations of interferon-alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 40: 365
5. Cameron RB, McIntosh JK, Rosenberg SA (1988) Syngeneic antitumor effects of combination immunotherapy with recombinant interleukin-2 and recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res 48: 5810